204 related articles for article (PubMed ID: 21496210)
21. Follow-up to the pre-validation of a harmonised protocol for assessment of CYP induction responses in freshly isolated and cryopreserved human hepatocytes with respect to culture format, treatment, positive reference inducers and incubation conditions.
Abadie-Viollon C; Martin H; Blanchard N; Pekthong D; Bachellier P; Mantion G; Heyd B; Schuler F; Coassolo P; Alexandre E; Richert L
Toxicol In Vitro; 2010 Feb; 24(1):346-56. PubMed ID: 19497360
[TBL] [Abstract][Full Text] [Related]
22. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes.
Oleson FB; Berman CL; Li AP
Chem Biol Interact; 2004 Nov; 150(2):137-47. PubMed ID: 15535984
[TBL] [Abstract][Full Text] [Related]
23. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Steinberg M
Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
[TBL] [Abstract][Full Text] [Related]
24. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034.
Sahi J; Sinz MW; Campbell S; Mireles R; Zheng X; Rose KA; Raeissi S; Hashim MF; Ye Y; de Morais SM; Black C; Tugnait M; Keller LH
Chem Biol Interact; 2006 Feb; 159(2):156-68. PubMed ID: 16356485
[TBL] [Abstract][Full Text] [Related]
25. Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine.
Arbus C; Benyamina A; Llorca PM; Baylé F; Bromet N; Massiere F; Garay RP; Hameg A
Eur J Pharm Sci; 2007 Dec; 32(4-5):357-66. PubMed ID: 17951033
[TBL] [Abstract][Full Text] [Related]
26. Liver grafts preserved in Celsior solution as source of hepatocytes for drug metabolism studies: comparison with surgical liver biopsies.
Donato MT; Serralta A; Jiménez N; Pérez G; Castell JV; Mir J; Gómez-Lechón MJ
Drug Metab Dispos; 2005 Jan; 33(1):108-14. PubMed ID: 15448115
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.
Kumar G; Lau H; Laskin O
Cancer Chemother Pharmacol; 2009 May; 63(6):1171-5. PubMed ID: 19030860
[TBL] [Abstract][Full Text] [Related]
28. Assessment of a novel β2-adrenoceptor agonist, trantinterol, for interference with human liver cytochrome P450 enzymes activities.
Jiang K; Li K; Qin F; Lu X; Li F
Toxicol In Vitro; 2011 Aug; 25(5):1033-8. PubMed ID: 21466844
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes.
Kim KA; Park JY
Drug Metab Dispos; 2003 Sep; 31(9):1090-2. PubMed ID: 12920163
[TBL] [Abstract][Full Text] [Related]
30. Metabolism-mediated drug interaction potential of HS-23, a new herbal drug for the treatment of sepsis in human hepatocytes and liver microsomes.
Jeong HU; Lee JY; Kwon SS; Kim JH; Kim YM; Hong SW; Yeon SH; Lee SM; Cho YY; Lee HS
Arch Pharm Res; 2015 Feb; 38(2):171-7. PubMed ID: 25052959
[TBL] [Abstract][Full Text] [Related]
31. Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey.
Sonesson A; Koechling W; Stalewski J; Tankó LB; Rasmussen BB
Drug Metab Dispos; 2011 Oct; 39(10):1895-903. PubMed ID: 21768273
[TBL] [Abstract][Full Text] [Related]
32. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
[TBL] [Abstract][Full Text] [Related]
33. Interaction between 3,4‑dichlorophenyl‑propenoyl‑sec.‑butylamine (3,4‑DCPB), an antiepileptic drug, and cytochrome P450 in rat liver microsomes and recombinant human enzymes in vitro.
Cheng HX; Lu YY; Wang X; Ren H; Li Q; Wang SM; Ding Y; Lou YQ; Zhang GL
Eur J Pharm Sci; 2018 Oct; 123():241-248. PubMed ID: 30010032
[TBL] [Abstract][Full Text] [Related]
34. Assessment of cytochrome P450 (1A2, 2B6, 2C9 and 3A4) induction in cryopreserved human hepatocytes cultured in 48-well plates using the cocktail strategy.
Gerin B; Dell'Aiera S; Richert L; Smith S; Chanteux H
Xenobiotica; 2013 Apr; 43(4):320-35. PubMed ID: 23153057
[TBL] [Abstract][Full Text] [Related]
35. Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin.
Babbar S; Chanda S; Bley K
Xenobiotica; 2010 Dec; 40(12):807-16. PubMed ID: 20863199
[TBL] [Abstract][Full Text] [Related]
36. In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine.
Chen Y; Liu L; Laille E; Kumar G; Surapaneni S
Cancer Chemother Pharmacol; 2010 Apr; 65(5):995-1000. PubMed ID: 20119716
[TBL] [Abstract][Full Text] [Related]
37. Induction of CYP2C genes in human hepatocytes in primary culture.
Gerbal-Chaloin S; Pascussi JM; Pichard-Garcia L; Daujat M; Waechter F; Fabre JM; Carrère N; Maurel P
Drug Metab Dispos; 2001 Mar; 29(3):242-51. PubMed ID: 11181490
[TBL] [Abstract][Full Text] [Related]
38. Luciferin IPA-based higher throughput human hepatocyte screening assays for CYP3A4 inhibition and induction.
Doshi U; Li AP
J Biomol Screen; 2011 Sep; 16(8):903-9. PubMed ID: 21832258
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of liposomal curcumin cytochrome p450 metabolism.
Mach CM; Chen JH; Mosley SA; Kurzrock R; Smith JA
Anticancer Res; 2010 Mar; 30(3):811-4. PubMed ID: 20393001
[TBL] [Abstract][Full Text] [Related]
40. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
Muschler E; Lal J; Jetter A; Rattay A; Zanger U; Zadoyan G; Fuhr U; Kirchheiner J
Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
